MedTrace Logo

Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury

NCT00208572 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2007-10-05

No results posted yet for this study

Summary

The proposal will assess the effectiveness of SRI treatment of anxiety following TBI. We hypothesize that participants will report significantly fewer and less severe anxiety symptoms after a 12-week course of citalopram than after a 12-week course of placebo.

Conditions

Interventions

DRUG

Citalopram

Sponsors & Collaborators

  • The Defense and Veterans Brain Injury Center

    collaborator FED

  • VA Palo Alto Health Care System

    collaborator FED

  • Hunter Holmes McGuire VA Medical Center

    collaborator FED

  • United States Naval Medical Center, San Diego

    collaborator FED

  • 59th Medical Wing

    collaborator FED

  • James A. Haley Veterans Administration Hospital

    collaborator FED

  • Walter Reed Army Medical Center

    lead FED

Principal Investigators

  • Michael Jaffee, MD · The Defense and Veterans Brain Injury Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208572 on ClinicalTrials.gov